Loading...
Kanabo Group Plc
KNB.L•LSE
Healthcare
Medical - Pharmaceuticals
£0.23
£-0.07(-25.00%)

Financial performance has remained strong, with revenue growing from $449000.00 in Q2 2023 to $694000.00 in Q2 2024. Gross profit continued to perform well, with margins at 5% in the latest quarter. Operating income reached -$1.70M in Q2 2024, holding a steady -244% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.05M. Net income rose to -$1.75M, keeping EPS at -$0.003. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan